High Blood Glucose and obesity could make a person more vulnerable to certain types of cancers and the best way to counter the threat is to lose weight.
“High Blood Glucose and obesity are associated with some types of cancer, including that of the pancreas, oesophagus and breast,” said Edwin Gale, professor of diabetes at Bristol University‘s division of medicine. He was in the city to address a conference organised byIntegrated Diabetes and Endocrinology Academy (Idea), Calcutta.
According to Gale, 40 per cent of these cancers are apparently caused by diabetes and obesity. “High Blood Glucose and obesity leads to insulin resistance in the body that can cause cancer. The best way to reduce insulin resistance is weight loss,” he explained.
“Fat and muscle cells need insulin to absorb glucose. But in an insulin-resistant person, these cells fail to adequately respond to circulate insulin and blood glucose levels rise,” said a doctor at the conference.
Gale said an obese person had a 30 per cent increased risk of suffering from cancer than a person of normal weight.
“An obese person with blood sugar is more susceptible to cancer than one who is not. Although the exact cause is not clear, the common belief is that insulin resistance is the underlying factor,” said Subhankar Chowdhury, head of endocrinology, SSKM Hospital.
Use Supplement for blood sugar:
FENFURO Regular intake of FENFURO can control the blood sugar level effectively. FENFURO is a first of its kind, safe nutraceutical derived from fenugreek seeds through a patented process. Through its unique scientific process, FENFURO concentrates the bioactive part of plants into a manageable dose, while removing the inert parts such as cellulose. Also, since a lot of healthy botanicals are not palatable, consuming their concentrate in capsule form in small dosage is a lot easier. FENFURO contains a rich variety of saponins and flavonoids. These substances are known to lower blood lipid level and help in insulin sensitization and glucose regulation. FENFURO is the first dual action insulin sensitizer.
The statement and product have not been evaluated by the FDA to diagnose, treat, cure or prevent any disease.